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ABSTRACT: Nipah virus (NiV) is an emerging and deadly
zoonotic paramyxovirus that is responsible for periodic epidemics
of acute respiratory illness and encephalitis in humans. Previous
studies have shown that the NiV V protein antagonizes host
antiviral immunity, but the molecular mechanism is incompletely
understood. To address this gap, we biochemically characterized
NiV V binding to the host pattern recognition receptor MDA5. We
ﬁnd that the C-terminal domain of NiV V (VCTD) is suﬃcient to
bind the MDA5SF2 domain when recombinantly co-expressed in
bacteria. Analysis by hydrogen−deuterium exchange mass
spectrometry (HDX-MS) studies revealed that NiV VCTD is conformationally dynamic, and binding to MDA5 reduces the
dynamics of VCTD. Our results also suggest that the β-sheet region in between the MDA5 Hel1, Hel2, and Hel2i domains exhibits
rapid HDX. Upon VCTD binding, these β-sheet and adjacent residues show signiﬁcant protection. Collectively, our ﬁndings suggest
that NiV V binding disrupts the helicase fold and dynamics of MDA5 to antagonize host antiviral immunity.
KEYWORDS: Nipah virus, V protein, MDA5, IFN antagonist, hydrogen−deuterium exchange mass spectrometry
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also contains a conserved histidine and several cysteine
residues, which likely form two zinc ﬁnger (ZnF) motifs
based upon sequence homology to PIV5 and MV VCTDs.18−22
Like other paramyxoviruses, NiV V proteins function as
interferon (IFN) antagonists to inhibit host antiviral signaling.
Earlier studies showed that the NiV V protein is a major
determinant of pathogenesis.23−25 Recombinant Nipah virus
Malaysia with V protein knockout (rNiVM-VKO) is severely
attenuated compared to WT virus or virus with W protein
knockout due to reduced inhibition of the innate immune
response; this allows for a potent neutralizing antibody
response and viral clearance.23 The lack of serious disease in
animals infected with rNiVM-VKO points to the V protein
having a prominent and early role in modulating immune
responses and controlling disease progression. NiV V targets
the host cytoplasmic pattern-recognition receptor (PRR)
melanoma diﬀerentiation-associated protein 5 (MDA5) that
detects viral RNAs and triggers IFN production and antiviral
gene expression to control viral infections.26−34 MDA5
contains a superfamily 2 (SF2) helicase domain preceded by

ipah virus (NiV) is an emerging zoonotic pathogen that
causes severe respiratory disease and encephalitis
associated with human fatalities.1−5 NiV was ﬁrst identiﬁed
in Malaysia and Singapore as the source of an outbreak of
disease among pigs and subsequently in humans.6,7 Since then,
recurring outbreaks have been documented in other parts of
Asia, primarily in Bangladesh and India, with case fatality rates
as high as 75%. Isolates from Malaysia and Bangladesh are
genetically distinct. While there is high nucleotide homology
(>91%) between the Malaysia and Bangladesh strains, the
sequence heterogeneity in NiV genes or proteins may account
for the diﬀerences in the transmission mode and rates.8,9
Currently, there are no approved, eﬀective prophylactics or
therapeutics available for NiV infection.
NiV, along with Hendra virus (HeV), are henipaviruses
within the paramyxovirus family of the nonsegmented,
negative-strand RNA viruses. These also include parainﬂuenza
virus 5 (PIV5), measles virus (MV), mumps virus (MuV), and
Sendai virus (SeV).10−13 The NiV genome encodes for four
nonstructural proteins (P, V, W, and C) that are generated
from the P gene and that function to inhibit host innate
immune responses. V and W proteins are produced through
RNA editing during transcription, and the C protein is
expressed through leaky scanning and an alternative initiation
codon site during ribosomal translation.2,10,14−17 Thus, P, V,
and W proteins share a common N-terminal domain (NTD),
but each has distinct C-terminal domains (CTDs). NiV VCTD
© 2021 The Authors. Published by
American Chemical Society
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Figure 1. NiV VCTD protein binds the MDA5SF2 domain. (a) Domain architecture and constructs of NiV P/V/C and MDA5 proteins. (b) co-IP of
NiV P gene-encoded proteins with MDA5. NiV P, V, C, VCTD, or empty vector (EV) plasmids encoding a fusion N-terminal FLAG epitope tag
were co-transfected with the human MDA5 or EV plasmid encoding a fusion N-terminal HA epitope tag. HEK293T cells were harvested at 48 h
after co-transfection. Cells were lysed, and the resultant lysate was clariﬁed as a whole cell extract (WCE). Anti-FLAG M2 beads were incubated
with each WCE and washed before elution with the FLAG peptide for Western blot. (c) NiV V co-immunoprecipitates with MDA5 truncations.
(d) NiV V co-immunoprecipitates with the MDA5SF2 domain. (e) NiV VCTD co-immunoprecipitates with the MDA5SF2 domain. (f) NiV V cannot
pull-down MDA5SF2 when expressed separately, and lysates were mixed together prior to co-IP. Images show representative experimental data of
three biological repeats.

all bind MDA5 and not RIG-I.33−35 In addition, NiV V targets
the STAT1 transcription factor. NiV P/VNTD binds to STAT1
and prevents its tyrosine phosphorylation and activation,14,36−38 whereas NiV WCTD contains a nuclear localization
sequence that allows it to also sequester STAT1 in the nucleus

two tandem N-terminal caspase activation and recruitment
domains (CARDs) that are involved in autoregulatory
activities and a CTD that binds double-stranded RNA
(dsRNA). Previous studies showed that V proteins of several
paramyxoviruses, including NiV, PIV5, HeV, SeV, and MuV,
119
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To further validate the interaction between NiV VCTD and
the MDA5SF2 domain and to show direct binding, we next
transfected the MDA5SF2 and NiV V constructs into separate
pools of HEK293T cells, mixed the WCEs together, and
performed the co-IP. However, we found that NiV V does not
co-IP with MDA5SF2 under these conditions (Figures 1f and
S1d). We next tested if recombinant maltose binding protein
(MBP)-tagged NiV VCTD and the MDA5SF2 domain expressed
separately in Escherichia coli bind in in vitro pulldown assays.
When we mixed lysates containing each protein together prior
to pulldown, we observed no binding (Figure 2a), consistent

and prevent transcriptional activation of IFN-stimulated
genes.38−41 Although these studies show that NiV can target
MDA5 and STAT1, how NiV proteins mediate these functions
remains incompletely deﬁned. Furthermore, the amino acid
sequence encoded by NiV P/V/WNTD is diﬀerent from other
paramyxovirus P proteins, suggesting that NiV may use a
distinct mechanism to antagonize IFN responses.
Here, we employed a combined approach to validate and to
characterize biochemically the interaction between NiV V and
MDA5. Co-immunoprecipitation (co-IP) and in vitro pulldown
assays demonstrated direct binding between NiV V and MDA5
proteins. Further analysis deﬁned the regions NiV VCTD and
the MDA5 SF2 (MDA5 SF2) domain as suﬃcient for
interactions. Hydrogen−deuterium exchange mass spectrometry (HDX-MS) on NiV VCTD revealed a dynamic protein that
becomes protected from HDX upon binding to the MDA5SF2
domain. HDX-MS studies on MDA5SF2 identiﬁed a highly
dynamic β-sheet region that exposes a potential site for VCTD
binding. Additional HDX-MS studies on the NiV VCTD/
MDA5SF2 complex suggest that NiV VCTD binds to surfaces
adjacent to this dynamic region within the SF2 domain.
Altogether, our results support that NiV V binding disrupts the
MDA5 fold and dynamics to antagonize host antiviral
immunity.

■

RESULTS
NiV VCTD Binds to MDA5SF2. To further characterize the
interaction between NiV V and MDA5, we ﬁrst co-transfected
plasmids encoding HA-tagged MDA5 and Flag-tagged P, V, or
C proteins from the Malaysia strain (accession AAK50551)
into HEK293T cells. We used the Malaysia strain sequence,
since this was the ﬁrst Nipah virus identiﬁed, even though the
Bangladesh strain has been shown to be more pathogenic. Flag
co-IP revealed that the NiV V protein immunoprecipitates with
full-length MDA5 (Figures 1a,b and S1a), as shown
previously.18,33−35,42−47 Transfections with the NiV V CTD
(VCTD; encoding residues G407−G456) displayed stronger coIP of full-length MDA5 relative to full-length V. Previous
studies on full-length V revealed that the V protein alone is
largely intrinsically disordered with some residual secondary
structure and that regions in V can undergo a structural
transition upon interactions with a binding partner.48 Our
results here raise the possibility that other regions in the fulllength V protein may prevent the VCTD from binding MDA5
through interactions with other host factors during co-IP that
can restrict the conformation of V or the accessibility of the
VCTD. While this needs further testing, the isolated VCTD is
suﬃcient and strongly binds toMDA5, consistent with earlier
observations.33−35,43
To deﬁne the minimal region in MDA5 that interacts with
the NiV VCTD, we generated a series of MDA5 truncations that
were co-transfected with NiV VCTD and subjected to co-IP
studies. Our results indicate that both MDA5ΔCARD (encoding
residues 291−1025) and MDA5ΔCTD (encoding residues 1−
890) co-immunoprecipitates with NiV V, suggesting that the
CARDs and the C-terminal RNA binding domain are not
required for the NiV V interaction (Figures 1c and S1b). We
next tested binding to the MDA5SF2 domain (encoding
residues 291−890) that contains the DECH helicase and
pincer region. We found that MDA5SF2 co-immunoprecipitates
with both NiV V full length (Figures 1d and S1c) and to its
isolated VCTD (Figures 1e and S1c).

Figure 2. Co-expression of NiV VCTD with MDA5SF2 produces a
soluble protein complex. (a) NiV VCTD co-expressed with MDA5SF2
showed direct interactions by in vitro pulldown assay. E. coli cells coexpressing both MBP−NiV VCTD and MDA5SF2 were lysed and
clariﬁed prior to a MBP pulldown assay on amylose resin in the
absence (left) and presence (right) of 5 mM EDTA. (b) Co-lysis of
bacterial cells containing NiV VCTD and MDA5SF2 that do not pulldown each other. E. coli cells expressing NiV VCTD were mixed with
cells expressing MDA5SF2 prior to homogenization. The resultant
supernatant after clariﬁcation of the co-lysates was applied to amylose
resin and washed as in (a). (c) Individually puriﬁed NiV VCTD in E.
coli cells does not pull-down MDA5SF2. Amylose beads were
incubated with either the MBP tag alone or with the MBP−NiV
VCTD protein as bait mixed with a separately puriﬁed MDA5SF2
domain as prey. After stringent washing, proteins bound on the
resin were eluted with buﬀer containing 15 mM maltose.
120

https://doi.org/10.1021/acsinfecdis.1c00403
ACS Infect. Dis. 2022, 8, 118−128

ACS Infectious Diseases

pubs.acs.org/journal/aidcbc

with our observations in HEK293T cells. When we performed
pulldown assays using individually puriﬁed proteins, we also
observed no detectable binding (Figure 2b). Together, these
results suggest that the interaction between NiV VCTD and the
MDA5SF2 domain requires additional host factors that may be
present during co-IP or requires co-translational assembly. We
next tested co-expression of MBP−NiV VCTD with the
MDA5SF2 domain in bacteria and found that MBP-tagged
NiV VCTD binds directly to the MDA5SF2 domain by pulldown
assay (Figure 2c, left panel), eliminating the possibility that
other factors are involved. Because the NiV VCTD contains
highly conserved cysteine-rich domains that are predicted to
form two Zn ﬁnger motifs,20,21,49 analogous to that observed in
the PIV5 crystal structures18,50 (Figure S1e), we also
performed in vitro pulldown assays in the presence of
ethylenediaminetetraacetic acid (EDTA). We ﬁnd that
addition of EDTA had no impact on binding (Figure 2c,
right panel), suggesting the formation of a stable complex.
Together, our results indicate that simultaneous expression of
the MDA5SF2 domain with NiV VCTD may be necessary for
proper folding and stability.
MDA5SF2 Can Modulate the Dynamics of the NiV
VCTD. Because the structures for NiV V or VCTD are not
currently known, we used HDX-MS to structurally characterize
the NiV VCTD. HDX-MS reports on changes in solvent
accessibility or hydrogen bonding of backbone amide groups;
thus, HDX is sensitive to protein dynamics, conformational
changes, and binding sites.51,52 Peptide digestion and bottomup analysis of the isolated MBP-tagged NiV VCTD produced 24
unique peptides, reporting on 84% of the construct (Figure
S2a). The most N-terminal residue of every peptide is prone to
fast back-exchange and thus is not considered in the
interpretation.53 More N-terminal residues show very low
HDX at short incubation times (residues 405−434) (Figure
3a). The C-terminal end of VCTD (residues 433−454) shows a
high degree of HDX, even after short HDX incubation times,
indicating a more disordered structure.
Analysis of the MBP−NiV VCTD/MDA5SF2 complex reveals
that the N-terminus of NiV VCTD is protected from HDX and
throughout much of the VCTD (Figure 3b). One region of the
protein (represented by two peptides: 402−415 aa and 426−
432 aa) indicate a static binding site (with slow on/oﬀ rates),
where the HDX kinetic curves of the unbound (free state) and
bound (in complex with MDA5SF2) protein run in parallel
(Figure 3b,c). The intervening region (415−416 aa and 417−
425 aa) shows increased HDX for the bound state, suggesting
that these peptides become less hydrogen-bonded or more
exposed for the MBP−NiV VCTD/MDA5SF2 complex than in
the unbound state; in fact, part of this region of VCTD (residues
415−416) in the complex shows very high HDX after longer
incubation times, consistent with little hydrogen bonding. In
the region containing residues 433−445, the kinetic plots for
unbound and bound converge with time, suggesting that the
region becomes more dynamic and less bonded (faster oﬀ
rate) than the more N-terminal binding regions. The Cterminal end of VCTD (residues 445−456) shows little to no
diﬀerence in HDX between bound and unbound. The VCTD
contains a histidine (H408) and seven cysteine (C415, C427,
C431, C443, C445, C448, and C452) residues that are
conserved in all paramyxovirus VCTDs.22,45 Parallels to PIV5 V
proteins suggest that these residues are important for zinc
coordination and formation of a Zn ﬁnger motif.18,19 The data
shown here reveal that H408, C415, C448, and C452, which

Article

Figure 3. HDX-MS highlights the disordered nature of NiV VCTD and
conﬁrms strong binding with MDA5SF2. (a) Heat map showing the
deuterium uptake extent of free MBP−NiV VCTD. HDX-MS of
unbound MBP−NiV VCTD after 10 s through 14,400 s, where the
extent of deuterium incorporation is indicated by using the color
gradient. (b) Woods’ plot showing peptide-level HDX diﬀerences
between unbound MBP−NiV VCTD and MDA5SF2-bound MBP−NiV
VCTD. The horizontal bars depict each peptide length spanning a
region of the sequence and showing cumulative diﬀerences in absolute
deuterium uptake between the bound vs unbound state of NiV VCTD.
Decreases in deuterium uptake are shown as negative values (blue),
and increases are shown as positive values (red). Gray shading
indicates the global signiﬁcance range (p < 0.01) for which diﬀerences
are considered statistically signiﬁcant. Those peptides not reporting a
signiﬁcant diﬀerence are shown in dark gray. Error bars depict the
propagated error in technical duplicate measurements across all time
points. Vertical orange shading shows previously reported binding
residues from the PIV5 binding study and sequence alignment. (c)
Representative HDX kinetic plots showing peptides covering NiV
VCTD. Unbound NiV VCTD (black) vs NiV VCTD bound with the
MDA5SF2 domain (red). (d) Representative kinetic plots showing
HDX diﬀerences observed of the N-terminal MBP tag. Kinetic plots
are shown for the MBP tag region of MHT-NiV VCTD for free MBP−
NiV VCTD (black) vs MBP−NiV V-CTD co-expressed with the
MDA5SF2 domain (red). The bar given above shows the identity of
the peptide with reference to the composition of the protein
construct.

form the larger ﬁrst Zn ﬁnger, undergo less changes in HDX
upon MDA5SF2 binding compared to the four central cysteine
121
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Figure 4. HDX-MS reveals changes in solvent accessibility in the MDA5SF2 structure when compared to the MDA5SF2/NiV VCTD complex. (a)
Heat map showing the deuterium uptake extent of free MDA5SF2 relative to secondary structural elements (top) combined with segmented Woods’
plot showing peptide-level HDX diﬀerences between unbound MDA5SF2 and MDA5SF2 bound with MBP−NiV VCTD (bottom). HDX of the
unbound MDA5SF2 construct after 10 s through 14,400 s deuterium exchange times, where deuterium incorporation is indicated using a color scale.
Secondary structures extracted from the dsRNA-bound MDA5SF2 crystal structure (PDB 4GL2) are shown above for reference. In the Woods’ plot,
the horizontal bars depict each peptide spanning a region of the sequence and showing cumulative diﬀerences in absolute deuterium uptake
between the bound and unbound states of the MDA5SF2 domain. Decreases in diﬀerential deuterium uptake are shown as negative values (blue),
and increases are shown as positive values (red). Gray shading indicates the global signiﬁcance range (p < 0.01) for which diﬀerences are
considered statistically signiﬁcant. Those peptides not reporting a signiﬁcant diﬀerence are shown in gray. Error bars depict the propagated error in
technical duplicate measurements across all time points. (b) HDX of free MDA5SF2 after 10 s of HDX mapped onto the MDA5SF2 structure. The %
HDX was mapped onto the MDA5SF2 in the crystal structure bound to dsRNA (PDB 4GL2, ΔCTD, left) and onto MDA5SF2 (displaying residues
534−809 and827−836) rotated 90° (right). The HDX extent is indicated by the scale bar to the right: n.d., not determined deuterium uptake due
to limited peptide coverage (white). (c) Deuterium uptake of free MDA5SF2 after 14,400 s of HDX mapped onto the MDA5SF2 structure. The %
HDX was mapped onto the MDA5SF2 in the crystal structure bound to dsRNA (PDB 4GL2, ΔCTD, left). (d) Peptide-level diﬀerential HDX
mapped to the dsRNA-bound MDA5 crystal structure. The statistically signiﬁcant diﬀerential HDX for representative peptides shown in a
(bottom) were mapped onto the dsRNA-bound MDA5SF2 (displaying residues 534−809 and827−836) structure as shown in (b) (right).
Diﬀerential HDX is indicated by the color bar. (e) Comparison with the PIV5 VCTD-bound MDA5SF2 Hel2 and Hel2i crystal structure (PDB 4I1S).
122
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of the slow exchanging core noted in the free state (Figure 4b);
the largest decreases in HDX are clustered around the region
surrounding β11, including α17 through β10 and β11
(residues 763−806), and the ﬂexible region between α14
and α15 through β8 (residues 700−724) (Figure 4a,d). Note
that the long peptides encompassing residues 744−784 and
covering α17 show decreased HDX, but the shorter peptides
encompassing residues 744−762 and before α17 do not.
Interestingly, the more dynamic β-strands, β7 and β12, show
no evidence of diﬀerential HDX within the MDA5SF2 domain/
MBP−NiV VCTD complex. Overall, all these observations are
consistent with the crystal structure of MDA5SF2 Hel2 and
Hel2i domains in complex with the V protein of another
paramyxovirus, PIV5 (Figure 4e).18 PIV5 V protein displaces
the MDA5SF2 β7 and β12 in the Hel2 domain and forms a
continuous β-sheet with β11. Comparison of our cumulative
diﬀerential HDX results for the MDA5SF2/MBP−NiV VCTD
complex with the MDA5SF2/PIV5 V structure (PDB 4I1S)
reveals that the same decreased HDX around β11 observed in
the presence of NiV VCTD would be expected for the PIV5 V
protein (Figure 4d,e), suggesting that like the PIV5 V protein,
NiV VCTD likely binds to these regions adjacent to Hel2 and
pincer domains, causing HDX protection.
MDA5 regions with increased HDX are also observed in the
MDA5SF2/MBP−NiV VCTD complex, in particular at the ends
of α-helices at the interface between Hel2 and Hel2i (Figure
4a,d). Increased HDX, suggesting increased dynamics or
solvent exposure, occurs upon binding between α12 and α13
(residues 610−622) and between β8 and α16 (residues 725−
732). In other words, these regions show relatively less HDX in
the unbound state with the exception of the linker regions
already reported in the crystal structure (Figure 4a,b),
indicating that they undergo conformation changes distal to
the binding sites, and these changes open the structure.57
Collectively, our data suggest that NiV VCTD not only binds
MDA5SF2 similar to the PIV5 V protein but also induces
changes in the dynamics in other regions within MDA5; these
latter changes may impact its antiviral activity.

residues C427, C431, C443, and C445, which form the second
Zn ﬁnger, that are more protected from HDX upon MDA5SF2
binding. Our results here conﬁrm that regions encompassing
the central cysteine residues are important for binding to
MDA5.
Given that our NiV VCTD is fused to an MBP-tag, we wanted
to rule out the possibility that MBP was binding to MDA5.
Most regions of the MBP tag show little to no statistically
signiﬁcant diﬀerences between MBP−NiV VCTD unbound or
bound with the MDA5SF2 domain (Figure 3d). However, some
regions of the MBP-tag show increased HDX, including the
region encompassing the His6-tag and linker residues, which
may be a result of steric eﬀects between the larger MBP
molecule and NiV VCTD; these interactions are lost when
MBP−NiV VCTD is bound to the MDA5SF2 domain. This
would manifest as an increase in HDX of some regions on NiV
VCTD when comparing to the bound complex. Thus, the
importance of the N-terminus of NiV VCTD, where the low
HDX in the free state (residues 405−425) may be caused by
the presence of MBP, is underestimated, and the observed
large increase in the exposure of NiV VCTD in the free state
(residues 415−422) is likely to be a consequence of the MBPtag. While previous studies demonstrated the importance of
residue I414 in interference with MDA5 activity,45 we cannot
draw conclusions conﬁrming or refuting the importance of
I414; however, it is clear that the intrinsically disordered VCTD
adopts a more ordered structure, especially with respect to the
second Zn ﬁnger, in a relatively static binding interaction with
MDA5SF2.
NiV VCTD Binds and Modulates MDA5SF2 Dynamics.
Peptic digestion and bottom-up analysis of the MDA5SF2
domain, containing Hel1, Hel2, Hel2i, and pincer domains,
produced 237 unique peptides (Figure S2b). Most of the
MDA5SF2 showed low HDX rates, consistent with the high α
helical content reported in the crystal structure (PDB 4GL2)
(Figure 4a,b). Several regions, however, showed high
deuterium exchange rates in parts of Hel2 (β7 and β12 of
the central β-sheet region and α18), Hel1 (α9), and pincer
(α19) domains, even early in the HDX experiment (Figure
4a,b), suggesting that these regions are more dynamic and
conformationally ﬂexible than those reported in the dsRNAbound MDA5SF2 crystal structure. This is consistent with the
role of SF2 domains in binding RNA and adenosine 5′triphosphate that were described previously.54−56 Interestingly,
the central β sheet shows mixed dynamic motion; we observed
low HDX for β9, β10, and β8 throughout the experiment, low
HDX for β11 at short times that increases with longer times,
and high HDX for β12 and β7 even after short times [Figure
4b (inset)]. After 4 h of HDX, the Hel1, Pincer, and part of the
Hel2 domains eventually accumulate a high degree of
deuterium, but the Hel2i domain remains largely unexchanged,
suggesting little conformational diversity and dynamic motion
of this α-helix bundle (Figure 4c).
We next evaluated the MDA5SF2 domain in the context of
the MDA5SF2/MBP−NiV VCTD complex. Binding to MBP−
NiV VCTD resulted in both increases and decreases in HDX of
several regions of the MDA5SF2 domain, as shown in the
Woods’ diﬀerential HDX plot (Figure 4a). Within the Hel1
domain, decreased HDX is observed in the regions of α1
through β1 (residues 306−328), whereas increased HDX is
observed around α3 through α4 (residues 373−382). The
most pronounced diﬀerence in HDX is the protection
observed in the Hel2 domain (Figure 4a,d) on the periphery

■

DISCUSSION
The NiV V protein is a critical virulence factor that potently
inhibits host innate immune responses.22−25 The importance
of the NiV V protein in this process was established by earlier
studies where rNiVM strains deﬁcient in the V protein failed to
suppress immune responses and caused disease in an animal
model.23 The NiV V protein directly binds to the PRR MDA5
to prevent IFN signaling.34,35,43,46,47 To develop a better
understanding of the role of NiV V in this process, we
performed a biochemical and structural characterization of the
interaction between NiV V and MDA5. Co-IP assays
demonstrated that the NiV VCTD binds to the MDA5SF2
domain when co-transfected and not to other domains. In
vitro pulldown assays using puriﬁed recombinant proteins and
co-puriﬁcation of cell lysates containing individually expressed
proteins do not show direct interactions. However, coexpression and co-puriﬁcation of the recombinant MBP−NiV
VCTD/MDA5SF2 domain complex provide evidence of a
soluble, intact complex. This is not surprising as heterologous
protein overexpression in E. coli can result in misfolded or
insoluble proteins. Several factors contribute to the production
of stable proteins, including cofactors and post-translational
modiﬁcations, which may be absent in E. coli. Co-expression
with a binding partner can help overcome some of these
123
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strands. Furthermore, the HDX results suggest that this
displacement does not change the conformational preference
of the MDA5SF2 β-strands from the RNA-free unbound state
but would prevent formation of the central β-sheet observed in
the RNA-bound MDA5SF2 crystal structure (PDB 4GL2).54
This suggests that NiV V may sterically hinder “closing” of the
RNA-free dynamic conformation of MDA5SF2.
Our HDX-MS results revealed binding-induced conformational changes in regions distal to the binding interface of NiV
VCTD/MDA5SF2 that may have additional implications for
MDA5SF2 binding with dsRNA. Regions near α13 and α14 of
the Hel2i subdomain and α6 of the Hel2 subdomain show
increased HDX when MDA5SF2 is bound to NiV VCTD,
indicating either a binding-induced decrease in the α-helical
character and/or an increase in dynamic motion. We observe
decreased HDX of a remote region near α17 of the Hel2
subdomain and α1 and β1 of the Hel1 domain and some
exposure near α3 and α4. These remote conformational
changes present important potential implications for NiV VCTD
binding with the MDA5SF2 domain, wherein NiV VCTD may
impede dsRNA binding to the MDA5SF2 domain despite its
remote binding site. Thus, our HDX results indicate that the
NiV V protein binding site on the MDA5SF2 domain is similar
but not entirely the same as that of PIV5 V.18,46
We have shown here that the β-sheet region within the
MDA5SF2 domain is dynamic, and the regions at the interface
become protected upon binding with NiV VCTD. Formation of
the NiV VCTD/MDA5SF2 domain complex stabilizes the VCTD,
including in the region encompassing the conserved central
cysteine residues, and leads to allosteric changes in MDA5 that
likely disrupts its activity. Thus, modulation of the conformational dynamics within MDA5 may present a potential
mechanism for immune evasion by a highly pathogenic RNA
virus.

barriers and facilitate production of functional proteins by
reducing conformational ﬂexibility.58 Moreover, the NiV V
protein has been recently described as an intrinsically
disordered protein (IDP) that lacks a signiﬁcantly folded
structure and conformational stability.48 IDPs like the NiV V
protein can undergo binding-induced folding during complex
formation that is dependent on the nature of the binding
partner.59−61 Thus, co-expression and co-translation in a
recombinant system can generate complexes that may not
form by mixing individual components, especially when
involving IDPs.
Structural analysis of the co-expressed and co-puriﬁed NiV
VCTD/MDA5SF2 domain complex revealed extensive HDX
protection throughout NiV VCTD. Diﬀerential HDX-MS
analysis for residues covering residues 408−415 and 426−
432 indicates static binding with MDA5SF2 (i.e., low on−oﬀ
rates). A region encompassing residues 433−445 suggests
weaker bonding or a more dynamic interaction with nearby
MDA5SF2 residues (i.e., higher oﬀ rates). The importance of
conserved residues R409, E411, I414, and C431 that attenuate
NiV V binding to MDA545 is consistent with the static
localized binding shown by the HDX-MS analysis; C443 and
C445 are within the more dynamic binding site, but there is no
evidence of C448 participation. Notably, these regions also
cover the four central cysteine residues that form the second
zinc ﬁnger (i.e., C427, C431, C443, and C445). While these
results cannot conﬁrm the importance of the cysteine side
chains, the HDX results are evidence of direct binding of these
regions with MDA5SF2 or binding-induced stabilization of the
intrinsically disordered unbound VCTD backbone. Despite this
observation, addition of EDTA did not disrupt the interaction
between NiV VCTD and MDA5SF2, suggesting that the Zn motif
is either protected within the complex or that higher
concentrations are needed to extract the zinc ions.
HDX-MS analysis of free MDA5SF2 is largely consistent with
the reported crystal structure of MDA5 SF2 bound to
dsRNA;54,62 however, the HDX data also identiﬁed a highly
exchanging region comprising β7, β12, and α18 of the Hel2
domain, α9 of the Hel1 domain, and much of α19 of the pincer
domain. The extensive HDX observed for β7 and β12 at short
times and that observed for β11 at longer times indicates that
this β-sheet structure is not static in the free state but rather
very dynamic.
Diﬀerential HDX-MS analysis of NiV VCTD binding to the
MDA5SF2 domain indicates a relatively static binding
interaction covering the vicinity of β11 (Figure 4) but no
eﬀect on the dynamic strands of the β-sheet region, β7 and
β12. The location of this binding site is interesting because if
the β-sheet structure is maintained in the unbound state,
binding-induced protection should not be observed for β11.
The lack of statistically signiﬁcant diﬀerences in HDX between
bound and unbound within this dynamic region indicates that
this region is locked in an exposed or open conformation.
There are signiﬁcant parallels to what we observe by HDXMS of the NiV VCTD/MDA5SF2 domain complex and the
reported crystal structure of PIV5 VCTD/MDA5SF2 (PDB
4I1S). In the PIV5 VCTD/MDA5SF2 structure, the PIV5 VCTD
replaces the MDA5SF2 β7 and β12 strands in the central βsheet. PIV5 V binding with MDA5SF2 is associated with
decreased formation of RNA-bound signaling MDA5
oligomers, possibly disrupting SF2−SF2 or SF2−RNA-binding
domain interactions.18 The results reported here are consistent
with NiV VCTD, similarly displacing the MDA5SF2 β7 and β12

■

METHODS
Recombinant Protein Production. The gene encoding
the NiV V protein (accession AAK50551) was codonoptimized for expression in E. coli (GeneScript, NJ) prior to
subcloning into a modiﬁed pET15b plasmid containing a
maltose-binding protein (MBP) tag followed by a His6 tag.
MDA5 and MDA5SF2 were ampliﬁed from human complementary DNA by polymerase chain reaction. All sequences
were conﬁrmed with Sanger sequencing. Recombinant proteins
were expressed in E. coli BL21(DE3) cells at 18 °C for 16 h
with 0.25 mM IPTG induction. Cells were pelleted down by
centrifugation and re-suspended in lysis buﬀer containing 50
mM Tris-HCl (pH 8.0), 300 mM NaCl, and protease
inhibitors prior to lysis with an EmulsiFlex-C5 homogenizer
(Avestin, Canada). Lysate was clariﬁed by centrifugation at
60,000g and then used for pulldown assays or further protein
puriﬁcation using a series of aﬃnity, ion exchange, and gel
ﬁltration columns (GE Healthcare, IL). The MBP-tag on
MDA5SF2 was cleaved using TEV protease and removed by
aﬃnity puriﬁcation. Final protein samples were assessed by
SDS-PAGE.
Co-immunoprecipitation. HEK293T cells were grown in
6-well plates in Dulbecco’s modiﬁed Eagle medium containing
10% fetal bovine serum. Cells were transfected at approximately 80% conﬂuency with a mixture of one plasmid
encoding NiV proteins and the other encoding MDA5 protein
for co-IP experiments. Cells were harvested by centrifugation
at 48 h after transfection. After washing once with phosphate124
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buﬀered saline, cells were either stored in −80 °C for use or
suspended in lysis buﬀer containing 50 mM Tris-HCl, pH 8.0,
280 mM NaCl, 2 mM EGTA, 0.4 mM EDTA, 10% glycerol,
0.5% IGEPAL CA630 (Sigma-Aldrich), and a protease
inhibitor cocktail. The lysate was clariﬁed with centrifugation
at 14,000 rpm for 15 min, and the clariﬁcation was repeated
three times. The resultant supernatant, WCE hereafter, was
used to incubate with anti-FLAG M2 magnetic beads (SigmaAldrich, M8823) at 4 °C. The beads were pelleted down using
a magnetic rack after 1 h of incubation and washed ﬁve times
with the lysis buﬀer. Proteins bound on the beads were eluted
with 150 ng/mL FLAG peptide (Sigma-Aldrich, F3290).
Samples from the WCE and the elution were transferred to the
poly(vinylidene diﬂuoride) membrane for Western blot after
resolving by SDS-PAGE. Mouse anti-FLAG (F3165) and antiHA (Sigma-Aldrich, H3663) monoclonal antibodies were used
as primary antibodies to detect viral proteins and human
proteins with the corresponding epitope, respectively. Goat
anti-mouse IgG−HRP conjugated antibody (Santa Cruz, SC2005) was used as a secondary antibody for the western blot.
Blot images were taken from Amersham Imager 600 (GE
Healthcare).
MBP Pulldown Assay. MBP pulldown assay was similar to
that previously reported.63 Brieﬂy, E. coli lysate clariﬁed by
centrifugation or puriﬁed proteins was incubated with amylose
resin at high ﬂow (New England Biolabs, E8022L) in binding
buﬀer for 30 min with moderate agitation in a cold room. The
resin was washed six times with washing buﬀer and eluted with
binding buﬀer containing 15 mM maltose. Samples were
resolved by SDS-PAGE and stained with Coomassie blue for
visualization. For co-lysate preparation, cells expressing either
the viral protein or human MDA5SF2 were re-suspended in lysis
buﬀer containing 150 mM NaCl and mixed before
homogenization.
Hydrogen−Deuterium Exchange Mass Spectrometry
(HDX-MS). All chemical reagents used in HDX-MS experiments were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise noted. HDX-MS analyses were carried out, as
previously described,64,65 on puriﬁed MBP−NiV VCTD,
MDA5 SF2 , and the co-expressed MBP−NiV V-CTD/
MDA5SF2 protein complex (stock solutions 40 μM per protein
in PBS, pH 7.4). Brieﬂy, HDX was initiated by diluting 4 μL of
a protein stock solution with a ninefold excess of PBS in D2O
(Cambridge Isotope Laboratories, Inc., Tewksbury, MA) (ﬁnal
composition 90/10% v/v D2O/H2O). The mixture was
exchanged on ice for 0, 10, 30, 60, 360, 900, or 144,000 s,
and the HDX was quenched by adding 30 μL of a quench
buﬀer (3 M urea in PBS, pH 2.4). In-solution digestion was
performed using protease type XIII from Aspergillus saitoi
(fungal XIII, PBS pH 2.4) immediately after quenching and
incubated for 3 min at 22 °C.
All liquid chromatography/mass spectrometry (LC/MS)
analyses were performed using a custom-built liquid
chromatography (LC) assembly coupled to an LTQ-FTICR
mass spectrometer (Thermo Fisher, Waltham, MA). The LC
system incorporated online pepsin protease digestion using a
custom-prepared immobilized pepsin column (2 × 20 mm),
followed by peptide trapping and desalting on a ZORBAX
Eclipse XDB C8 column (2.1 × 15 mm, Agilent, Santa Clara,
CA) and reversed-phase peptide separation with an XSelect
CSH C18 column (2.1 × 50 mm, Waters, Manchester, UK).
All HDX-MS time points were analyzed in duplicate.
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Using the same setup and procedure, proteolytic mapping
analyses were performed prior to HDX on nondeuterated
aliquots of the protein stock solutions, except that tandem MS
in the data-dependent mode was used. The top six most
abundant fragment ions from each scan were selected for MS/
MS analysis. The MS/MS ﬁles were analyzed using Byonic and
Byologic (Protein Metrics, San Carlos, CA) to generate a list of
identiﬁed peptides to be followed in the HDX-MS analyses.
The search was also carried out against reverse sequences of
the proteins to discard ambiguous assignments.
All HDX-MS analyses were processed using HDExaminer
(version 2.5.1, Sierra Analytics, Modesto, CA); adjustment of
LC boundaries and validation of MS interferences were
performed manually on all peptides. Woods’ plot peptide
cumulative HDX diﬀerences were calculated as the sum of all
diﬀerences at all time points in daltons [∑(Dcoexpressed) −
∑(Dfree)]. The standard errors of the mean were propagated
through the calculation and shown as error bars. The global
signiﬁcance limit was calculated as previously described.66,67
Brieﬂy, the pooled standard deviation was calculated for all
time points and all peptides within each state (i.e., bound and
unbound). The pooled standard deviations were used to
calculate the population standard error of the mean, and this
standard error was used with a two-tailed t-test value (p <
0.01) to calculate the conﬁdence interval distribution for
diﬀerences in HDX across the dataset. Statistically signiﬁcant
diﬀerences for representative peptides were mapped onto
structures using PyMOL. For a summary of all HDX data, see
the Supporting Information.
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